Aclarion cuts losses but delayed report shows continued financial stress

BROOMFIELD — Aclarion Inc. (Nasdaq: ACON), a Broomfield-based medical-device startup, cut its year-over-year net loss in more than half during the second quarter of 2023 but questions remain as to whether the company has the cash to continue operations over the next few periods. 

The company posted sales of $17,000 in the second quarter of 2023, up from about $10,000 in the same period last year.

Aclarion’s net loss was just under $1.5 million, an improvement on a loss of nearly $3.6 million in the second quarter of 2022. 

The company is a health care technology firm that uses biomarkers and proprietary augmented…